293 related articles for article (PubMed ID: 17544310)
1. Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI.
Auclair D; Hopwood JJ; Lemontt JF; Chen L; Byers S
Mol Genet Metab; 2007 Aug; 91(4):352-61. PubMed ID: 17544310
[TBL] [Abstract][Full Text] [Related]
2. Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: enzyme dose and interval.
Auclair D; Hein LK; Hopwood JJ; Byers S
Pediatr Res; 2006 Apr; 59(4 Pt 1):538-43. PubMed ID: 16549525
[TBL] [Abstract][Full Text] [Related]
3. Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats.
Auclair D; Finnie J; Walkley SU; White J; Nielsen T; Fuller M; Cheng A; O'Neill CA; Hopwood JJ
Pediatr Res; 2012 Jan; 71(1):39-45. PubMed ID: 22289849
[TBL] [Abstract][Full Text] [Related]
4. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
[TBL] [Abstract][Full Text] [Related]
5. Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats.
Turner CT; Hopwood JJ; Bond CS; Brooks DA
Mol Genet Metab; 1999 Jul; 67(3):194-205. PubMed ID: 10381327
[TBL] [Abstract][Full Text] [Related]
6. Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen.
Auclair D; Finnie J; White J; Nielsen T; Fuller M; Kakkis E; Cheng A; O'Neill CA; Hopwood JJ
Mol Genet Metab; 2010 Feb; 99(2):132-41. PubMed ID: 19896877
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age--a sibling control study.
McGill JJ; Inwood AC; Coman DJ; Lipke ML; de Lore D; Swiedler SJ; Hopwood JJ
Clin Genet; 2010 May; 77(5):492-8. PubMed ID: 19968667
[TBL] [Abstract][Full Text] [Related]
8. Monitoring dose response of enzyme replacement therapy in feline mucopolysaccharidosis type VI by tandem mass spectrometry.
Crawley A; Ramsay SL; Byers S; Hopwood J; Meikle PJ
Pediatr Res; 2004 Apr; 55(4):585-91. PubMed ID: 14711884
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.
Ruane T; Haskins M; Cheng A; Wang P; Aguirre G; Knox VW; Qi Y; Tompkins T; O'Neill CA
Mol Genet Metab; 2016 Feb; 117(2):157-63. PubMed ID: 26776148
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy in Mucopolysaccharidosis VI: evidence for immune responses and altered efficacy of treatment in animal models.
Brooks DA; King BM; Crawley AC; Byers S; Hopwood JJ
Biochim Biophys Acta; 1997 Aug; 1361(2):203-16. PubMed ID: 9300802
[TBL] [Abstract][Full Text] [Related]
11. Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis type VI disease.
Di Natale P; Villani GR; Parini R; Scarpa M; Parenti G; Pontarelli G; Grosso M; Sersale G; Tomanin R; Sibilio M; Barone R; Fiumara A
Biotechnol Appl Biochem; 2008 Mar; 49(Pt 3):219-23. PubMed ID: 17672828
[TBL] [Abstract][Full Text] [Related]
12. Replacement therapy in Mucopolysaccharidosis type VI: advantages of early onset of therapy.
Auclair D; Hopwood JJ; Brooks DA; Lemontt JF; Crawley AC
Mol Genet Metab; 2003 Mar; 78(3):163-74. PubMed ID: 12649061
[TBL] [Abstract][Full Text] [Related]
13. Advantages of using same species enzyme for replacement therapy in a feline model of mucopolysaccharidosis type VI.
Bielicki J; Crawley AC; Davey RC; Varnai JC; Hopwood JJ
J Biol Chem; 1999 Dec; 274(51):36335-43. PubMed ID: 10593925
[TBL] [Abstract][Full Text] [Related]
14. Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis.
Muñoz-Rojas MV; Horovitz DD; Jardim LB; Raymundo M; Llerena JC; de Magalhães Tde S; Vieira TA; Costa R; Kakkis E; Giugliani R
Mol Genet Metab; 2010 Apr; 99(4):346-50. PubMed ID: 20036175
[TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.
Harmatz P; Giugliani R; Schwartz I; Guffon N; Teles EL; Miranda MC; Wraith JE; Beck M; Arash L; Scarpa M; Yu ZF; Wittes J; Berger KI; Newman MS; Lowe AM; Kakkis E; Swiedler SJ;
J Pediatr; 2006 Apr; 148(4):533-539. PubMed ID: 16647419
[TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy in a feline model of MPS VI: modification of enzyme structure and dose frequency.
Byers S; Crawley AC; Brumfield LK; Nuttall JD; Hopwood JJ
Pediatr Res; 2000 Jun; 47(6):743-9. PubMed ID: 10832731
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures.
Harmatz P
Turk J Pediatr; 2010; 52(5):443-9. PubMed ID: 21434527
[TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome.
Crawley AC; Brooks DA; Muller VJ; Petersen BA; Isaac EL; Bielicki J; King BM; Boulter CD; Moore AJ; Fazzalari NL; Anson DS; Byers S; Hopwood JJ
J Clin Invest; 1996 Apr; 97(8):1864-73. PubMed ID: 8621770
[TBL] [Abstract][Full Text] [Related]
19. Autologous transplantation of retrovirally transduced bone marrow or neonatal blood cells into cats can lead to long-term engraftment in the absence of myeloablation.
Simonaro CM; Haskins ME; Abkowitz JL; Brooks DA; Hopwood JJ; Zhang J; Schuchman EH
Gene Ther; 1999 Jan; 6(1):107-13. PubMed ID: 10341882
[TBL] [Abstract][Full Text] [Related]
20. Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: A resurvey study.
Horovitz DDG; Leão EKEA; Ribeiro EM; Martins AM; Barth AL; Neri JICF; Kerstenetzky M; Siqueira ACM; Ribeiro BFR; Kim CA; Santos FC; Franco JFS; Lichtvan LCL; Giuliani LR; Rodrigues MDCS; Bonatti RCF; Teixeira TB; Gonçalves A; Lourenço CM; Pereira ASS; Acosta AX
Mol Genet Metab; 2021 May; 133(1):94-99. PubMed ID: 33678523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
